TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
52.90
+4.75 (9.87%)
Mar 24, 2026, 1:30 PM CST

TaiMed Biologics Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
611.35610.16491.78563.01413.44
Revenue Growth (YoY)
0.19%24.07%-12.65%36.18%-42.77%
Cost of Revenue
351.9398.94266.54347.3329.49
Gross Profit
259.45211.23225.23215.7183.96
Selling, General & Admin
72.2675.2997.1974.45109.72
Research & Development
381.84388.21294.28333.12460.6
Operating Expenses
454.1463.49391.46407.57570.32
Operating Income
-194.65-252.27-166.23-191.86-486.37
Interest Expense
-10.71-12.6-14.81-10.1-7.44
Interest & Investment Income
28.9433.978.464.344.03
Currency Exchange Gain (Loss)
-26.352.0448.69-11.38
Other Non Operating Income (Expenses)
8.655.054.782.443.45
EBT Excluding Unusual Items
-167.78-199.51-165.76-146.48-497.7
Gain (Loss) on Sale of Investments
---29.05-122.8126.76
Gain (Loss) on Sale of Assets
--2.32--0.01
Pretax Income
-167.78-201.83-194.81-269.29-470.93
Net Income
-167.78-201.83-194.81-269.29-470.93
Net Income to Common
-167.78-201.83-194.81-269.29-470.93
Shares Outstanding (Basic)
275268253252252
Shares Outstanding (Diluted)
275268253252252
Shares Change (YoY)
2.55%6.08%0.18%0.04%0.03%
EPS (Basic)
-0.61-0.75-0.77-1.07-1.87
EPS (Diluted)
-0.61-0.75-0.77-1.07-1.87
Free Cash Flow
168.48-387.61-31.75-608.77-220.96
Free Cash Flow Per Share
0.61-1.45-0.13-2.41-0.88
Gross Margin
42.44%34.62%45.80%38.31%20.31%
Operating Margin
-31.84%-41.34%-33.80%-34.08%-117.64%
Profit Margin
-27.44%-33.08%-39.61%-47.83%-113.90%
Free Cash Flow Margin
27.56%-63.52%-6.46%-108.13%-53.44%
EBITDA
-41.04-104.49-17.72-42.22-336.3
EBITDA Margin
-6.71%-17.13%-3.60%-7.50%-81.34%
D&A For EBITDA
153.61147.78148.51149.64150.07
EBIT
-194.65-252.27-166.23-191.86-486.37
EBIT Margin
-31.84%-41.34%-33.80%-34.08%-117.64%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.